JHOP - Supplements

Rx Profiler The PARP Inhibitor Rucaparib in the Maintenance Therapy of Recurrent Ovarian Carcinoma: Highlights from the ARIEL3 Clinical Trial

JHOP - Supplements

Ovarian cancer is the most lethal gynecologic cancer and the fifth leading cause of cancer death among women in the United States.¹ No effective screening tests are available, and more than 70% of patients are diagnosed with advanced-stage disease.²

Abemaciclib (Verzenio™), a Novel CDK4/6 Inhibitor, in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

JHOP - Supplements

Based on current incidence rates, 12.4% of women born in the United States today will develop breast cancer at some time during their life.¹ At the time of diagnosis, breast cancer is generally considered local, but eventually approximately 20% of patients will experience either locoregional or distant disease recurrence.²

Review of Ribociclib for Advanced Hormone Receptor–Positive Breast Cancer

JHOP - Supplements

Approximately 75% of breast cancers rely on ER signaling to grow and survive.² Endocrine therapy, which blocks the growth-promoting activity of estrogen, represents the primary intervention for early- and advanced-stage ER-positive breast cancer.³ However, some patients do not respond to endocrine therapy (ie, de novo resistance), and some patients who initially respond to therapy have disease that progresses during therapy (ie, acquired resistance).³

Diagnosis and Management of Polycythemia Vera

JHOP - Supplements

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) that has undergone a major evolution over the past decade.

Results 1 - 4 of 4